Buy & Sell Gitlab Inc (GTLB) – Gitlab Inc Price Today
Aura AI Summary
Key Stats
- $3.90BMarket Cap
- TechnologySector
- -32.99%3M Drawdown
- $2.64BEnterprise Value
- -Dividend Yield
- 57% Buy | 43% SellTrading Activity
- 56 daysTypical Hold Time
Gitlab Inc (GTLB) is currently valued at a market capitalization of $3.90B, with an enterprise value of $2.64B. Over the past 52 weeks, Gitlab Inc has traded between a low of $19.42 and a high of $53.43, highlighting its annual price range. Over the past three months, Gitlab Inc has recorded a drawdown of -32.99%, reflecting recent price volatility. On average, investors hold Gitlab Inc for approximately 56 days, indicating typical investor behavior on the platform.
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Most Recent News
NevGold upsizes financing to C$42M, advancing US antimony-gold project with near-term production plans.
NevGold Corp. has increased its brokered private placement financing from C$25 million to over C$42 million due to strong institutional demand. The Vancouver-based junior miner is developing the Limousine Butte gold-antimony project in Nevada, target...
Quantum Cyber secures exclusive drone tech license amid $55B US drone warfare budget boost
Quantum Cyber has secured an exclusive license for BP United's autonomous drone technology, including a sky defense platform capable of over 25 km range and fully autonomous operations. This move positions Quantum Cyber to capitalize on the Trump adm...
Corbus Pharmaceuticals to present at RBC and Jefferies healthcare conferences in May and June 2026
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focused on oncology and obesity therapies, announced CEO Yuval Cohen will present corporate updates and meet investors at two major healthcare conferences in New York: the RBC Capital ...